Severe Asthma
Conditions
Brief summary
Asthma is the most common chronic respiratory disorder in children. Despite significant advances in understanding of asthma, available therapies fail to alter the natural history and progression of the disease. Airway epithelial cells are continuously exposed to and injured by environmental irritants, such as viruses and pollutants, and as such are ideally situated to orchestrate airway function in response to these stimuli. Severe or difficult-to-treat asthma in children is a complicated disorder characterized by ongoing symptoms and persistent airway inflammation and oxidant stress despite corticosteroid treatment. Although severe asthma is likely a heterogeneous disorder, affected children similar clinical features, including gas trapping, bronchial hyperresponsiveness, and aeroallergen sensitization. However, the molecular and cellular pattern of inflammation in children with severe asthma are not uniform : some investigators have found increased eosinophils and TH2 derived cytokines, others have noted noneosinophilic patterns with neutrophil activation. Given the heterogeneity of the inflammatory response in children with severe asthma, additional methods to distinguish severe asthma are needed.
Interventions
PROCEDUREbiopsies
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children 0-18 years * patients followed regularly for at least one year. * The diagnosis of asthma is increased according to the criteria of the Global Initiative for Asthma (GINA): children with a history of recurrent episodes of bronchial obstruction. * children with severe asthma defined by the American Thoracic Society (ATS): Severe asthma is defined by the presence of a major criterion: the need for high doses of inhaled corticosteroids (budesonide dose equivalent 400 micro g) and least two of the five minor criteria: * The daily use of beta 2 long-acting or short-term daily action (\<4 years) or anti-leukotrienes associated with inhaled corticosteroids Daily or almost daily use of beta-2 short-acting Permanent-bronchial obstruction (FEV \<80% predicted FEV) * At least one emergency department visit for asthma exacerbations in France * At least 3 courses of oral corticosteroids per year
Exclusion criteria
* parents' refusal to participate in the study * refusal children to participate pathology underlying cardiac, neuromuscular, immunodeficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| analysis of bronchial biopsies | 12 months | Number of ciliated cells(units) versus cells(units) with mucus found by fields of interface of the culture |
Countries
France
Outcome results
None listed